Thromb Haemost 2002; 87(03): 544-546
DOI: 10.1055/s-0037-1613042
Letters to the Editor
Schattauer GmbH

The Differences in Thrombolytic Effects of Administrated Recombinant t-PA between Japanese and Caucasians

Shigeru Ueshima
1   Department of Physiology, Kinki University School of Medicine, Ohnohigashi, Osaka, Japan
,
Osamu Matsuo
1   Department of Physiology, Kinki University School of Medicine, Ohnohigashi, Osaka, Japan
› Author Affiliations
Further Information

Publication History

Received 23 July 2001

Accepted after resubmission 27 November 2001

Publication Date:
14 December 2017 (online)

 

 
  • References

  • 1 Niitani H, Kawai C, Kimata S, Nakashima M, Yasuda T, Kanazawa T, Aoki N, Kajiwara N, Kanmatsuse K, Hayakawa H, Takano T, Hirosawa K, Takeyama Y, Mizuno Y, Matsuda T, Yui Y, Hiramori K, Kodama K, Mitsudo K, Nobuyoshi M, Nakamura M. Dose-finding study of intravenous GMK-527 (rt-PA) for acute myocardial infarction: A multicenter double blind study [in Japanese]. Rinsho To Kenkyu 1989; 66: 587-601.
  • 2 Niitani H, Kawai C, Kimata S, Nakashima M, Yasuda T, Kanazawa T, Aoki N, Kajiwara N, Kanmatsuse K, Hayakawa H, Takano T, Hirosawa K, Takeyama Y, Mizuno Y, Matsuda T, Yui Y, Hiramori K, Kodama K, Mitsudo K, Nobuyoshi M, Nakamura M. Efficacy of intravenous GMK-527 (rt-PA) for acute myocardial infarction: A well controlled randomized study with envelope method [in Japanese]. Rinsho To Kenkyu 1989; 66: 602-14.
  • 3 Niitani H, Kawai C, Kanmatsuse K, Kimata S, Takano T, Takeyama Y, Yui Y, Nakashima M. Clinical usefulness of intravenous GMK-527 (rt-PA) for acute myocardial infarction: A Multi-center double blind study, comparison with urokinase [in Japanese]. Igaku No Ayumi 1991; 156: 429-51.
  • 4 Yui Y, Kawai T, Hosoda S, Aoki N, Kanmatsuse K, Takano T, Iwade K, Motomiya T, Yabe Y, Takatsu F, Haze K, Minamino R, Kodama K, Sato H, Hiasa Y, Hayasaki K, Nakashima M. Clinical efficacy of SUN9216 (modified tissue plasminogen activator) as compared Alteplase in patients with acute myocardial infarction: A multicenter randomized double-blind comparative study [in Japanese]. Jpn Pharmacol Ther 1997; 25: 269-99.
  • 5 Carney RJ, Murphy GA, Brandt TR, Daley PJ, Pickering E, White HJ, McDonough TJ, Vermilya SK, Teichman SL. for the RAAMI Study Investigators. Randomized angiographic trial of recombinant tissue-type plasminogen activator (Alteplase) in myocardial infarction. J Am Coll Cardiol 1992; 20: 17-23.
  • 6 den Heijer P, Vermeer F, Ambrosioni E, Sadowski Z, López-Sendón JL, von Essen R, Beaufils P, Thadani U, Adgey J, Pierard L, Brinker J, Davis RF, Smalling RW, Wallentin L, Caspi A, Pangeri A, Trickett L, Hauck C, Henry D, Chew P. on behalf of the InTIME Investigators. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction. A double-blind, randomized angiographic trial of Lanoteplase versus Alteplase. Circulation 1998; 98: 2117-25.
  • 7 Neuhaus K, von Essen R, Tebbe U, Vogt A, Roth M, Riess M, Niederer W, Forycki F, Wirtzfeld A, Maeurer W, Limbourg P, Merx W, Haerten K. Improved thrombolysis in acute myocardial infarction with front-loaded administration of Alteplase: Results of the rt-PA-APSAC Patency Study (TAPS). J Am Coll Cardiol 1992; 19: 885-91.
  • 8 Cannon CP, Gibson CM, McCabe CH, Adgey AAJ, Schweiger MJ, Sequeira RF, Grollier G, Giugliano RP, Frey M, Mueller HS, Steingart RM, Weaver WD, Van de Werf F, Braunwald E. for the Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. TNK-tissue plasminogen activator compared with front-loaded Alteplase in acute myocardial infarction. Results of the TIMI 10B Trial. Circulation 1998; 98: 2805-14.
  • 9 Mueller HS, Rao AK, Forman SA. and the TIMI Investigators. Thrombolysis in Myocardial Infarction (TIMI): Comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1987; 10: 479-90.
  • 10 Topol EJ, Morris DC, Smalling RW, Schumacher RR, Taylor C, Nishikawa A, Liberman HA, Collen D, Tufte ME, Grossbard EB, O’Neill WW. A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (Activase) in acute myocardial infarction. J Am Coll Cardiol 1987; 09: 1205-13.
  • 11 Smalling RW, Schumacher R, Morris D, Harder K, Fuentes F, Valentine RP, Battey Jr LL, Merhige M, Pitts DE, Lieberman HA, Nishikawa A, Adyanthaya A, Hopkins A, Grossbard E. Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: Results of a multicenter randomized trial of two dosage regimens. J Am Coll Cardiol 1990; 15: 915-21.
  • 12 Ross AW, Gao R, Coyne KS, Boyle D, Chin J, Yao K, Yang Y, Qin X, Yao M, Qiao S. Response to fibrinolytics in an Asian acute MI population: Different from the West. Circulation. 1999 100. (Suppl.): I-303.
  • 13 Iso H, Folson AR, Sato S, Wu KK, Shimamoto T, Koike K, Iida M, Komachi Y. Plasma fibrinogen and its correlates in Japanese and US population samples. Arterioscler Thromb 1993; 13: 783-90.
  • 14 Iso H, Folson AR, Koike KA, Sato S, Wu KK, Shimamoto T, Iida M, Komachi Y. Antigens of tissue plasminogen activator and plasminogen activator inhibitor 1: Correlates in nonsmoking Japanese and Caucasian Men and Women. Thromb Haemost 1993; 70: 475-80.
  • 15 Kangsadalampai S, Board PG. The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood 1998; 92: 2766-70.
  • 16 Murata M. Genetic polymorphisms associated with thrombotic disorders in the Japanese population. Fibrinolysis & Proteolysis 2000; 14: 155-64.